Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shanghai Pharmaceutical
Pharma
Hutchmed inks $608M asset sale to focus on ADC development
To advance its “innovative medicines business,” Hutchmed will sell its 45% interest in Shanghai Hutchison for $608 million, the company said.
Kevin Dunleavy
Jan 2, 2025 11:10am
China's NRDL, Biocon-Viatris and more—Fierce Pharma Asia
Dec 10, 2021 8:45am
Syntegon and Shanghai Pharma to build lab for novel drug process
Dec 9, 2021 10:40am
China's PD-1s, Fujifilm, Sinopharm and more—Fierce Pharma Asia
Jan 8, 2021 9:08am
Shanghai Pharma maps $1.18B construction project in hometown hub
Jan 5, 2021 7:43am
FiercePharmaAsia—Astellas, Brii's $260M, Sun and more
May 25, 2018 9:30am